Skip to main content

Table 1 Demographic data

From: Multivariable analysis to determine if HIV-1 Tat dicysteine motif is associated with neurodevelopmental delay in HIV-infected children in Malawi

 

Tat C31S polymorphism (TatCS) n = 24 (72.7 %)

Dicysteine motif (TatCC) n = 9 (27.3 %)

p-value

Age (months) mean ± SD*

20.2 ± 8.0

17.1 ± 7.1

0.261 t-test

Gender (% male)

45.8

44.4

>0.999 Fisher’s exact

Maternal age (years) mean ± SD

27.6 ± 4.8

26.7 ± 4.7

0.622 t-test, unequal

Log plasma viral load (copies/mL) mean ± SD

5.7 ± 0.6

6.4 ± 0.5

0.008 t-test, unequal

Log CSF viral load (copies/mL) mean ± SD

3.8 ± 1.0

4.3 ± 0.5

0.139 t-test

Viral load ratio (CSF:plasma) mean ± SD

0.04 ± 0.10

0.01 ± 0.01

0.401 t-test

Maternal ARTa use (% on ART)

19.1

0.0

0.552 Fisher’s exact

PMTCTb (% that received sdNVP)

30.0

77.8

0.041 Fisher’s exact

Breastfeeding at enrollment (%)

30.4

25.0

>0.999 Fisher’s exact

Breastfed for >6months (%)

60.9

83.3

0.633 Fisher’s exact

Neurodevelopmental scores (z-scores)

t-test, unequal

 Fine motor

−1.9 ± 1.1

−2.4 ± 1.4

0.361

 Gross motor

−4.0 ± 1.7

−3.9 ± 1.3

0.783

 Cognitive

−1.9 ± 1.1

−1.5 ± 0.8

0.199

 Expressive communication

−1.9 ± 1.2

−1.9 ± 0.9

0.869

 Receptive communication

−1.4 ± 0.9

−1.3 ± 0.7

0.916

  1. * Sample size: age, gender, log viral load, log CSF viral load, viral load ratio, (n = 33); maternal age (n = 30); maternal ART use, PMTCT, breastfed for >6months (n = 29); breastfeeding at enrollment (n = 31)
  2. aART—antiretroviral therapy
  3. bPMTCT—prevention of mother to child transmission; the use of antepartum antiretroviral therapy to prevent the peripartum transmission of HIV; all mothers that received PMTCT, received single-dose nevirapine (sdNVP)